Patent Application
20200179935
Microfluidic devices are miniature fluidic devices dealing with small fluidic volumes, usually in the sub-milliliter range. Microfluidic devices may have micromechanical structures (microchannels, microtracks, micropaths, microvalves and others) and employ various fluid-moving mechanisms, such as mechanical parts (e.g., micropumps) hydro-pneumatic devices/methods and electrically-based effects (electrophoretic, dielectrophoretic, electro-osmotic, electrowetting, opto-electrowetting, and variations of these effects as well as other effects).
Some embodiments disclosed herein provide filler fluids for a microfluidic device comprising a silicone oil and a siloxane block co-polymer solubilized in the silicone oil, wherein the siloxane block co-polymer is substantially immiscible with an aqueous liquid. In some embodiments, less than about 0.1% of the volume fraction of the siloxane block co-polymer in the filler fluid is miscible with aqueous liquid. In some embodiments, the siloxane block co-polymer comprises a siloxane backbone and a functionalized side chain. In some embodiments, the functionalized side chain comprises a hydrophilic head group. In some embodiments, the siloxane block co-polymer is represented in Formula I:
wherein n≥0, m≥0, and R is selected from the group consisting of a polyacrylamide, a polysaccharide, a polyglycol, a carboxylate, a carboxylic acid, a sulfonate, a sulfate, an ethylene glycol, an amine, an ammonium, a carbohydrate, a carbonate, and a silicate. In some embodiments, the siloxane block co-polymer is selected from the group consisting of CMS-222, CMS-221, FMS 736, FMS-141, APT-263 and MCR-C12 available from Gelest (Morrisville, Pa.). In some embodiments, the concentration of the siloxane block co-polymer in the filler fluid is about 0.02% w/w to about 0.1% w/w. In some embodiments, the concentration of the siloxane block co-polymer in the filler fluid is about 0.05% w/w. In some embodiments, the silicone oil comprises polydimethylsiloxane (PDMS). In some embodiments, the siloxane block co-polymer is (hydroxypropyleneoxypropyl) methylsiloxane-dimethylsiloxane co-polymer. In some embodiments the surface tension of the filler fluid and a droplet of aqueous liquid is between about 3 to about 12 dynes/cm. In some embodiments less than about 0.1% of the volume fraction of the siloxane block co-polymer in the filler fluid is miscible with the aqueous buffer.
Some embodiments disclosed herein provide fluidic devices comprising a plurality of sample droplets dispersed in a filler fluid comprising a siloxane block co-polymer solubilized in silicone oil. In some embodiments, the silicone oil is polydimethylsiloxane (PDMS). In some embodiments, the siloxane block co-polymer is (hydroxypropyleneoxypropyl) methylsiloxane-dimethylsiloxane co-polymer. In some embodiments, the filler fluid allows the sample droplets to form and move within the microfluidic device. In some embodiments, the filler fluid does not have an effect on a biological function of any components within the sample droplets. In some embodiments, the siloxane block co-polymer comprises a siloxane backbone and a functionalized side chain. In some embodiments, the functionalized side chain comprises a hydrophilic head group. In some embodiments, the hydrophilic head group of the siloxane block co-polymer is selected from the group consisting of a polyacrylamide, a polysaccharide, a polyglycol, a carboxylate, a carboxylic acid, a sulfonate, a sulfate, an ethylene glycol, a PEG, an amine, an ammonium, a carbohydrate, a carbonate, and a silicate. In some embodiments, the siloxane block co-polymer is represented in Formula I:
wherein n≥0, m≥0, and R is selected from the group consisting of a polyacrylamide, a polysaccharide, a polyglycol, a carboxylate, a carboxylic acid, a sulfonate, a sulfate, an ethylene glycol, a PEG, an amine, an ammonium, a carbohydrate, a carbonate, and a silicate. In some embodiments, the siloxane block co-polymer is selected from the group consisting of CMS-222, CMS-221, FMS 736, FMS-141, APT-263 and MCR-C12 available from Gelest (Morrisville, Pa.). In some embodiments, the concentration of the siloxane block co-polymer in the filler fluid is about 0.02% w/w to about 0.1% w/w. In some embodiments, the concentration of the siloxane block co-polymer in the filler fluid is about 0.05% w/w. In some embodiments, the filler fluid comprises polydimethylsiloxane (PDMS). In some embodiments, the surface tension between the droplets and the filler fluid is between about 3 and about 10-12 dynes/cm. In some embodiments, the microfluidic device is a digital microfluidic device employing a mechanism selected from electrowetting, opto-electrowetting, electrostatic, electrophoretic, dielectrophoretic, electro-osmotic, or a combination thereof. In some embodiments, each of the sample droplets includes a biological sample. In some embodiments, the biological sample includes a nucleotide molecule, such as DNA molecule. In some embodiments, the microfluidic device comprises a droplet actuator configured to move a sample droplet through the microfluidic device. In some embodiments, the microfluidic device comprises: (a) a substrate comprising a substrate surface; (b) an array of electrodes disposed on the substrate surface; (c) a dielectric layer disposed on the substrate surface and patterned to cover the electrodes; and (d) an electrode selector for sequentially activating and de-activating one or more selected electrodes of the array to sequentially bias the selected electrodes to an actuation voltage, whereby each of the droplets disposed on the substrate surface moves along a desired path defined by the selected electrodes. In some embodiments, the microfluidic devices comprise a plate spaced from the substrate surface by a distance to define a space between the plate and the substrate surface, wherein the distance is sufficient to contain the droplet disposed in the space. In some embodiments, the plate comprises a plate surface facing the substrate surface, and the plate surface is hydrophobic.
Some embodiments include a kit comprising a fluidics device and a container comprising a filler fluid, wherein the filler fluid comprises a siloxane block co-polymer and silicone oil. The kit may further comprise a container comprising an aqueous buffer that is substantially immiscible with the siloxane block co-polymer. The kit may also comprise a siloxane block co-polymer wherein less than about 0.1% of the volume fraction of the silicon block co-polymer in the filler fluid is miscible with the aqueous buffer. In one embodiment, the silicone oil comprises polydimethylsiloxane (PDMS). In one embodiment, the siloxane block co-polymer is (hydroxypropyleneoxypropyl) methylsiloxane-dimethylsiloxane co-polymer. In one embodiment, the fluidics device is an electrowetting, opto-electrowetting, electrostatic, electrophoretic, dielectrophoretic, or electro-osmotic device.
Another embodiment is a method of conducting droplet operations in a fluidic device comprising moving a plurality of aqueous droplets through the filler fluid within the fluidic device, wherein the filler fluid comprises a siloxane block co-polymer solubilized in a silicone oil and the plurality of aqueous droplets is substantially immiscible with the filler fluid. In one embodiment, the surface tension between the plurality of aqueous droplets and the filler fluid is between about 3 to about 12 dynes/cm. In one embodiment, moving the plurality of droplets comprises performing polymerase chain reaction. In one embodiment, moving the plurality of droplets comprises preparing a sample for a polynucleotide sequencing reaction. In some embodiments, the method may include moving the plurality of aqueous droplets comprising using electrowetting, opto-electrowetting, electrostatic, electrophoretic, dielectrophoretic, electro-osmotic, or a combination thereof to move the plurality of aqueous droplets. In some embodiments, moving the plurality of droplets comprises performing polymerase chain reaction (PCR). In some embodiments, moving the plurality of droplets comprises preparing a sample for a polynucleotide sequencing reaction.
It should be appreciated that all combinations of the foregoing concepts and additional concepts discussed in greater detail below (provided such concepts are not mutually inconsistent) are contemplated as being part of the inventive subject matter disclosed herein. In particular, all combinations of claimed subject matter appearing at the end of this disclosure are contemplated as being part of the inventive subject matter disclosed herein.
The present disclosure describes compositions and methods for improving droplet operations in microfluidic devices. For biomedical applications, some microfluidic devices are designed to conduct sample processing, including concentration, filtration, washing, dispensing, mixing, transport, sample splitting, sample lysing and other sample handling functions.
Microfluidic devices may include digital fluidic cartridges having a top plate, usually made of plastic, which is coated with a conductive coating layer, two hydrophobic layers with tracks or paths of electrode in between, a dielectric coating and a printed circuit board (PCB) bottom. The space between the two hydrophobic layers can be filled with a filler fluid which is immiscible or substantially immiscible with the sample fluid. In some embodiments the sample fluid uses electrowetting to move a sample through the filler fluid within the microfluidic device.
As used herein one fluid is immiscible in another fluid if they do not form a homogenous mixture when added together. Fluids that are immiscible will separate into different liquid layers. The term “substantially immiscible” as used herein refers to a fluid which, when mixed with a droplet phase, will almost completely separate into two discrete phases after equilibration, with only an insignificant portion of one fluid being mixed with the other fluid. For example, a substantially immiscible mixture may have a volume fraction of a first liquid that is less than about 0.5%, about 0.3%, about 0.1%, about 0.05% or about 0.01% miscible with a second fluid.
In some embodiments, the present disclosure provides fluidic devices such as digital microfluidic devices. In some embodiments, the present disclosure provides methods of improving droplets operation, sample analysis, devices life-span and robustness in fluidic devices that use a filler fluid. Electrowetting devices may comprise a hydrophobic filler fluid within the device and a hydrophilic aqueous sample mixed within a predetermined buffer that forms a sample droplet in the filler fluid. For the droplet to move efficiently within the device, a droplet surface tension of about 6-12 dynes/cm is normally desired in some embodiments. This target surface tension may be achieved by adding a surfactant in the buffer. However, for some types of assays the surfactant may negatively affect the assay operation, for example by inhibiting particular chemical reactions. Thus, some embodiments of the disclosure relate to improved filler fluids that contain a siloxane-based block co-polymer hydrophobic surfactant. In some embodiments, the siloxane-based block co-polymer surfactant can adjust the surface tension of the sample droplet within the filler fluid to be within the target range of about 6 to about 12 dynes/cm.
In some embodiments, the filler fluid includes a low-viscosity oil such as a silicone oil or hexadecane filler fluid. The low viscosity oil may have a viscosity of about 7 cSt or less, as one example. The filler fluid may also be or include a halogenated oil, such as a fluorinated or perfluorinated oil. In one embodiment, a polymer-based surfactant is added to the filler fluid to alter the surface tension of aqueous droplets moving within the filler fluid. In embodiments that use a poly(dimethyl)siloxane (PDMS) based filler fluid, the polymer surfactant may be soluble in PDMS, but not in the aqueous buffer. One class of polymers, siloxane based block co-polymers, has been identified to be soluble in such filler fluids, and insoluble in aqueous buffers. Accordingly, one embodiment is a microfluidic device that uses a siloxane-based block co-polymer surfactant within a PDMS filler fluid. It should be appreciated that the filler fluids disclosed herein are compatible with biomedical fluidic applications.
In some embodiments, the siloxane based block co-polymer surfactant includes a siloxane backbone that is functionalized with a linear hydrophilic side chain, such as a hydrophilic head group.
The following detailed description is directed to certain specific embodiments of the present application. In this description, reference is made to the drawings wherein like parts or steps may be designated with like numerals throughout for clarity. Reference in this specification to “one embodiment,” “an embodiment,” or “in some embodiments” means that a particular feature, structure, or characteristic described in connection with the embodiment can be included in at least one embodiment of the disclosure. The appearances of the phrases “one embodiment,” “an embodiment,” or “in some embodiments” in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments. Moreover, various features are described which may be exhibited by some embodiments and not by others. Similarly, various requirements are described which may be requirements for some embodiments but not other embodiments.
The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. The use of the term “including” as well as other forms, such as “include”, “includes,” and “included,” is not limiting. The use of the term “having” as well as other forms, such as “have”, “has,” and “had,” is not limiting. As used in this specification, whether in a transitional phrase or in the body of the claim, the terms “comprise(s)” and “comprising” are to be interpreted as having an open-ended meaning. That is, the above terms are to be interpreted synonymously with the phrases “having at least” or “including at least.” For example, when used in the context of a process, the term “comprising” means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound, composition, or device, the term “comprising” means that the compound, composition, or device includes at least the recited features or components, but may also include additional features or components.
As used herein, the term “droplet actuator” means a device for manipulating droplets. For examples of droplet actuators, see Pamula et al., U.S. Pat. No. 6,911,132, entitled “Apparatus for Manipulating Droplets by Electrowetting-Based Techniques,” issued on Jun. 28, 2005; Pamula et al., U.S. Patent Pub. No. 20060194331, entitled “Apparatuses and Methods for Manipulating Droplets on a Printed Circuit Board,” published on Aug. 31, 2006; Pollack et al., International Patent Pub. No. WO/2007/120241, entitled “Droplet-Based Biochemistry,” published on Oct. 25, 2007; Shenderov, U.S. Pat. No. 6,773,566, entitled “Electrostatic Actuators for Microfluidics and Methods for Using Same,” issued on Aug. 10, 2004; Shenderov, U.S. Pat. No. 6,565,727, entitled “Actuators for Microfluidics Without Moving Parts,” issued on May 20, 2003; Kim et al., U.S. Patent Pub. No. 20030205632, entitled “Electrowetting-driven Micropumping,” published on Nov. 6, 2003; Kim et al., U.S. Patent Pub. No. 20060164490, entitled “Method and Apparatus for Promoting the Complete Transfer of Liquid Drops from a Nozzle,” published on Jul. 27, 2006; Kim et al., U.S. Patent Pub. No. 20070023292, entitled “Small Object Moving on Printed Circuit Board,” published on Feb. 1, 2007; Shah et al., U.S. Patent Pub. No. 20090283407, entitled “Method for Using Magnetic Particles in Droplet Microfluidics,” published on Nov. 19, 2009; Kim et al., U.S. Patent Pub. No. 20100096266, entitled “Method and Apparatus for Real-time Feedback Control of Electrical Manipulation of Droplets on Chip,” published on Apr. 22, 2010; Velev, U.S. Pat. No. 7,547,380, entitled “Droplet Transportation Devices and Methods Having a Fluid Surface,” issued on Jun. 16, 2009; Sterling et al., U.S. Pat. No. 7,163,612, entitled “Method, Apparatus and Article for Microfluidic Control via Electrowetting, for Chemical, Biochemical and Biological Assays and the Like,” issued on Jan. 16, 2007; Becker et al., U.S. Pat. No. 7,641,779, entitled “Method and Apparatus for Programmable Fluidic Processing,” issued on Jan. 5, 2010; Becker et al., U.S. Pat. No. 6,977,033, entitled “Method and Apparatus for Programmable Fluidic Processing,” issued on Dec. 20, 2005; Decre et al., U.S. Pat. No. 7,328,979, entitled “System for Manipulation of a Body of Fluid,” issued on Feb. 12, 2008; Yamakawa et al., U.S. Patent Pub. No. 20060039823, entitled “Chemical Analysis Apparatus,” published on Feb. 23, 2006; Wu, U.S. Patent Pub. No. 20110048951, entitled “Digital Microfluidics Based Apparatus for Heat-exchanging Chemical Processes,” published on Mar. 3, 2011; Fouillet et al., U.S. Patent Pub. No. 20090192044, entitled “Electrode Addressing Method,” published on Jul. 30, 2009; Fouillet et al., U.S. Pat. No. 7,052,244, entitled “Device for Displacement of Small Liquid Volumes Along a Micro-catenary Line by Electrostatic Forces,” issued on May 30, 2006; Marchand et al., U.S. Patent Pub. No. 20080124252, entitled “Droplet Microreactor,” published on May 29, 2008; Adachi et al., U.S. Patent Pub. No. 20090321262, entitled “Liquid Transfer Device,” published on Dec. 31, 2009; Roux et al., U.S. Patent Pub. No. 20050179746, entitled “Device for Controlling the Displacement of a Drop Between Two or Several Solid Substrates,” published on Aug. 18, 2005; and Dhindsa et al., “Virtual Electrowetting Channels: Electronic Liquid Transport with Continuous Channel Functionality,” Lab Chip, 10:832-836 (2010). The disclosure of each of the references mentioned herein is incorporated herein by reference in its entirety.
Certain droplet actuators will include one or more substrates and electrodes associated with (e.g., layered on, attached to, and/or embedded in) the one or more substrates and arranged to conduct one or more droplet operations. In some embodiments, two or more substrates are arranged with a droplet operations gap therebetween. For example, certain droplet actuators will include a base (or bottom) substrate, droplet operations electrodes associated with the substrate, one or more dielectric layers atop the substrate and/or electrodes, and optionally one or more hydrophobic layers atop the substrate, dielectric layers and/or the electrodes forming a droplet operations surface. A top substrate may also be provided, which is separated from the droplet operations surface by a gap, commonly referred to as a droplet operations gap. Various electrode arrangements on the top and/or bottom substrates are discussed in the above-referenced patents and applications and certain novel electrode arrangements are discussed in the description of the present disclosure. During droplet operations droplets may remain in continuous contact or frequent contact with a ground or reference electrode. A ground or reference electrode may be associated with the top substrate facing the gap or the bottom substrate facing the gap. Where electrodes are provided on both substrates, electrical contacts for coupling the electrodes to a droplet actuator instrument for controlling or monitoring the electrodes may be associated with one or both plates. In some cases, electrodes on one substrate are electrically coupled to the other substrate so that only one substrate is in contact with the droplet actuator. In one embodiment, a conductive material (e.g., an epoxy, such as MASTER BOND™ Polymer System EP79, available from Master Bond, Inc., Hackensack, N.J.) provides the electrical connection between electrodes on one substrate and electrical paths on the other substrates, e.g., a ground electrode on a top substrate may be coupled to an electrical path on a bottom substrate by such a conductive material. Where multiple substrates are used, a spacer may be provided between the substrates to determine the height of the gap therebetween and define on-actuator dispensing reservoirs. The spacer height may, for example, be at least about 5 μm, about 100 μm, about 200 μm, about 250 μm, about 275 μm or more. Alternatively or additionally the spacer height may be at most about 600 μm, about 400 μm, about 350 μm, about 300 μm, or less. The spacer may, for example, be formed of a layer of projections form the top or bottom substrates, and/or a material inserted between the top and bottom substrates. One or more openings may be provided in the one or more substrates for forming a fluid path through which liquid may be delivered into the droplet operations gap. The one or more openings may in some cases be aligned for interaction with one or more electrodes, e.g., aligned such that liquid flowed through the opening will come into sufficient proximity with one or more droplet operations electrodes to permit a droplet operation to be effected by the droplet operations electrodes using the liquid. The base (or bottom) and top substrates may in some cases be formed as one integral component. One or more reference electrodes may be provided on the base (or bottom) and/or top substrates and/or in the gap. Examples of reference electrode arrangements are provided in the above referenced patents and patent applications.
For purposes of the present disclosure, the terms “layer” and “film” are used interchangeably to denote a structure or body that may be planar or substantially planar, and may be deposited on, formed on, coats, treats, or is otherwise disposed on another structure.
For purposes of the present disclosure, the term “communicate” (e.g., a first component “communicates with” or “is in communication with” a second component) is used herein to indicate a structural, functional, mechanical, electrical, optical, or fluidic relationship, or any combination thereof, between two or more components or elements. As such, the fact that one component is said to communicate with a second component is not intended to exclude the possibility that additional components may be present between, and/or operatively associated or engaged with, the first and second components.
For purposes of the present disclosure, it will be understood that when a given component such as a layer, region or substrate is referred to herein as being disposed or formed “on”, “in”, or “at” another component, that given component can be directly on the other component or, alternatively, intervening components (for example, one or more buffer layers, interlayers, electrodes or contacts) can also be present. It will be further understood that the terms “disposed on” and “formed on” are used interchangeably to describe how a given component is positioned or situated in relation to another component. Hence, the terms “disposed on” and “formed on” are not intended to introduce any limitations relating to particular methods of material transport, deposition, or fabrication.
For purposes of the present disclosure, it will be understood that when a liquid in any form (e.g., a droplet or a continuous body, whether moving or stationary) is described as being “on”, “at”, or “over” an electrode, array, matrix or surface, such liquid could be either in direct contact with the electrode, array, matrix or surface, or could be in contact with one or more layers or films that are interposed between the liquid and the electrode, array, matrix or surface.
As used herein, the term “reagent” describes any material useful for reacting with, diluting, solvating, suspending, emulsifying, encapsulating, interacting with, or adding to a sample material.
As used herein, the term “about”, when modifying a numerical value, refers to variation in the numerical value that can occur. For example, variations can occur through liquid handling procedures used for making solutions; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of the ingredients employed to make compositions or carry out methods. In one embodiment, the term “about” means within 1%, 5%, or up to 10% of the recited numerical value.
As used herein, “substantially” means to a great or significant extent. For example, one composition may be substantially the same as another composition when they are 95%, 96%, 97%, 98%, or 99% identical to one another.
All literature and similar material cited in this application, including, but not limited to, patents, patent applications, articles, books, treatises, and web pages, regardless of the format of such literature and similar materials, are expressly incorporated by reference in their entirety. In the event that one or more of the incorporated literature and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.
As used herein, the term “filler fluid” means a fluid that is associated with a fluidics device. The filler fluid may be used to fill the internal gaps of a fluidic, or microfluidic device, such as an electrowetting device. Within a fluidics device may be a droplet operations substrate that includes a droplet actuator for moving droplets within the device by electrical or electrowetting forces. The filler fluid may be substantially immiscible with a droplet phase of any aqueous sample placed within the fluidics device to render the droplet phase subject to electrode-mediated droplet operations. As one example, a droplet may be substantially immiscible with a filler fluid when less than about 0.1% of the volume fraction of the droplet liquid is miscible with the filler fluid liquid. Similarly, a silicone block co-polymer in a filler fluid may be substantially immiscible with a droplet liquid when less than about 0.1% of the volume fraction of the silicone block co-polymer in the filler fluid is miscible with the droplet liquid.
The droplet operations gap of a droplet actuator may be filled with a filler fluid. The filler fluid may, for example, be or include a low-viscosity oil, such as silicone oil or hexadecane filler fluid. The filler fluid may be or include a halogenated oil, such as a fluorinated or perfluorinated oil. The filler fluid may fill the entire gap of the droplet actuator or may coat one or more surfaces of the droplet actuator. Filler fluids may be conductive or non-conductive. Filler fluids may be selected to improve droplet operations and/or reduce loss of reagent or target substances from droplets, improve formation of microdroplets, reduce cross contamination between droplets, reduce contamination of droplet actuator surfaces, reduce degradation of droplet actuator materials, etc. For example, filler fluids may be selected for compatibility with droplet actuator materials. As an example, fluorinated filler fluids may be usefully employed with fluorinated surface coatings. Fluorinated filler fluids are useful to reduce loss of lipophilic compounds, such as umbelliferone substrates like 6-hexadecanoylamido-4-methylumbelliferone substrates (e.g., for use in Krabbe, Niemann-Pick, or other assays); other umbelliferone substrates are described in Winger et al., U.S. Patent Pub. No. 20110118132, entitled “Enzymatic Assays Using Umbelliferone Substrates with Cyclodextrins in Droplets of Oil,” published on May 19, 2011, the entire disclosure of which is incorporated herein by reference. Examples of suitable fluorinated oils include those in the Galden line, such as Galden HT170 (bp=170° C., viscosity=1.8 cSt, density=1.77), Galden HT200 (bp=200 C, viscosity=2.4 cSt, d=1.79), Galden HT230 (bp=230 C, viscosity=4.4 cSt, d=1.82) (all from Solvay Solexis); those in the Novec line, such as Novec 7500 (bp=128 C, viscosity=0.8 cSt, d=1.61), Fluorinert FC-40 (bp=155° C., viscosity=1.8 cSt, d=1.85), Fluorinert FC-43 (bp=174° C., viscosity=2.5 cSt, d=1.86) (both from 3M). In general, selection of perfluorinated filler fluids is based on kinematic viscosity (<7 cSt for example), and on boiling point (>150° C., for example, for use in DNA/RNA-based applications (PCR, etc.)). Filler fluids may, for example, be mixed with surfactants or other additives.
For example, additives may be selected to improve droplet operations and/or reduce loss of reagent or target substances from droplets, formation of microdroplets, cross contamination between droplets, contamination of droplet actuator surfaces, degradation of droplet actuator materials, etc. Compositions of the filler fluid, including surfactant doping, may be selected for improved performance with reagents used in the specific assay protocols and to have an effective interaction (or non-interaction) with droplet actuator materials. Examples of filler fluids and filler fluid formulations suitable for use with the methods and apparatus set forth herein are provided in Srinivasan et al, International Patent Pub. No. WO/2010/027894, entitled “Droplet Actuators, Modified Fluids and Methods,” published on Jun. 3, 2010; Srinivasan et al, International Patent Pub. No. WO/2009/021173, entitled “Use of Additives for Enhancing Droplet Operations,” published on Feb. 12, 2009; Sista et al., International Patent Pub. No. WO/2008/098236, entitled “Droplet Actuator Devices and Methods Employing Magnetic Beads,” published on Jan. 15, 2009; and Monroe et al., U.S. Patent Pub. No. 20080283414, entitled “Electrowetting Devices,” published on Nov. 20, 2008, the entire disclosures of which are incorporated herein by reference, as well as the other patents and patent applications cited herein. Fluorinated oils may in some cases be doped with fluorinated surfactants, e.g., Zonyl FSO-100 (Sigma-Aldrich) and/or others. A filler fluid may be a liquid. In some embodiments, a filler gas can be used instead of a liquid.
Embodiments include microfluidic devices for biomedical applications that include a filler fluid comprising a polymer solubilized in an oil, such as silicon oil. Different types and concentrations of polymer may be mixed with the oil to form a filler fluid that provides a target surface tension with droplets of aqueous buffer. Embodiments include methods of adjusting the surface tension between the filler fluid and the buffer to form sample droplets to be within a target range of surface tension. In cases where the filler fluid includes poly(dimethyl)siloxane (PDMS), the chosen surfactant may be soluble in PDMS, but not in the aqueous buffer that contains the sample. In one embodiment, one class of polymers, siloxane based block co-polymers, has been identified as soluble in PDMS and therefore useful in microfluidic devices for biomedical applications. Some embodiments of the present application are directed to filler fluids comprising a siloxane based block co-polymer which have a desirable interfacial tension (IFT).
As used herein, IFT refers to the surface tension between liquid phases, such as between the filler fluid and the aqueous liquid (such as buffer) contained within the droplet. In some embodiments, the IFT is measured by dispersing droplets containing certain reagents, e.g., buffers for biomedical applications, in a filler fluid. It should be appreciated that for different reagents, the desirable IFT or IFT range, may vary. Therefore, the filler fluids disclosed herein may be adjusted to achieve a desirable IFT value or IFT range for a certain reagent. The adjustment of the IFT of a filler fluid may be performed in a variety of ways, such as, but not limited to, varying the concentration of a siloxane based block co-polymer solubilized in the filler fluid. For example, the filler fluids disclosed herein may have an interfacial tension (IFT) that is about 3 dynes/cm, about 4 dynes/cm, about 5 dynes/cm, about 6 dynes/cm, about 7 dynes/cm, about 8 dynes/cm, about 9 dynes/cm, about 10 dynes/cm, about 11 dynes/cm, about 12 dynes/cm, about 13 dynes/cm, about 14 dynes/cm, about 15 dynes/cm, about 16 dynes/cm, about 17 dynes/cm, about 18 dynes/cm, about 19 dynes/cm, about 20 dynes/cm. The IFT may be greater or lesser than these values, or alternatively in a range that is between any two of the above values. In some embodiments, the filler fluid has an IFT of 8-15 dynes/cm. In some embodiments, the filler fluid has an IFT of 6-12 dynes/cm.
Accordingly, a siloxane based block co-polymer may be solubilized in the filler fluid in a range of concentrations so that a desirable IFT or IFT range may be achieved. The siloxane based block co-polymer may be solubilized in the filler fluid in various concentrations. In some embodiments, the siloxane based block co-polymer is about 0.001% w/w to about 5.0% w/w of the filler fluid, or about 0.005% w/w to about 2.5% w/w of the filler fluid, or about 0.01% w/w to about 1.0% w/w of the filler fluid, or about 0.02% w/w to about 0.1% w/w of the filler fluid, or about 0.04% w/w to about 0.1% w/w of the filler fluid, or a range defined by any of the two preceding values.
In some embodiments, the filler fluids allow droplet formation and movement. In some embodiments, the filler fluids should not have side effect on most biological function.
In some embodiments, the siloxane based block co-polymers comprise a siloxane backbone that is functionalized with a linear hydrophilic side chain, such as a hydrophilic head group. In some embodiments, the siloxane based block co-polymers comprise a structure represented by Formula I:
wherein n≥0, m≥0, and R may include, but not limited to, a polyacrylamide, a polysaccharide, a polyglycol, a carboxylate/carboxylic acid, a sulfonate/sulfate, an ethylene glycol/PEG, an amine/ammonium, a carbohydrate, a carbonate, a silicate, etc.
In some embodiments, the siloxane based block co-polymer is selected from the group consisting of: CMS-222 ((hydroxypropyleneoxypropyl) methylsiloxane-dimethylsiloxane co-polymer, 150-200 cSt), CMS-221 ((carbinol functional) methylsiloxane-dimethylsiloxane co-polymer, 125-150 cSt), CMS-626 (35% hydroxyethylene oxypropylmethylsiloxane)-(dimethylsiloxane) co-polymer, 550-650 cSt, CMS-832 ((hydroxyethyleneoxypropylmethylsiloxane)-(3,4-dimethoxyphenylpropyl)methylsiloxane-dimethylsiloxane terpolymer, 1,000-2,000 cSt), DBE 311 (dimethylsiloxane-(30-35% ethylene oxide) block co-polymer, 10 cSt), DBE 411 (dimethylsiloxane-(45-50% ethylene oxide) block co-polymer, 5-10 cSt), ABP-263 (dodecylmethylsiloxane-hydroxypolyalkyleneoxypropyl methylsiloxane co-polymer, 1,000-4,000 cSt), APT-263 ((60-70% dodecylmethylsiloxane)-(30-40% 2-phenylpropylmethylsiloxane) co-polymer, 1,100-1,300 cSt), MCR C61 (monodicarbinol terminated polydimethylsiloxane, asymmetric, 50-60 cSt), MCR-C12 (monocarbinol terminated polydimethylsiloxane, asymmetric, 15-20 cSt), DMS S31 (silanol terminated polydimethylsiloxane, 1,000 cSt), DBE-224 (dimethylsiloxane-(25-30% ethylene oxide) block co-polymer, 400 cSt), FMS 736 ((15-20% tridecafluorooctylmethylsiloxane)-(80-85% dimethylsiloxane) co-polymer, 4,00-7,000 cSt), FMS 121 (poly(3,3,3-trifluoropropylmethylsiloxane), 80-120 cSt), FMS 9922 (silanol terminated polytrifluoropropylmethylsiloxane, 150-250c cSt), FMS 9921 (silanol terminated polytrifluoropropylmethylsiloxane, 50-160 cSt), (all from Gelest, Morrisville, Pa.), Silsoft 900 (Momentive, Waterford, N.Y.), 482412 (Poly [dimethylsiloxane-co-methyl(3-hydroxypropyl)siloxane]-graft-poly(ethylene glycol) methyl ether, 45 cSt), 480320 (Poly[dimethylsiloxane-co-[3-(2-(2-hydroxyethoxy)ethoxy)propyl]methyl siloxane], 75 cSt), 480290 (Poly(dimethylsiloxane), monoglycidyl ether terminated, 65 cSt), 481246 (Poly(dimethylsiloxane), bis(hydroxyalkyl) terminated, 100 cSt), 481963 (Poly(dimethylsiloxane), hydroxy terminated, 750 cSt), 481955 (Poly(dimethylsiloxane), hydroxy terminated, 65 cSt), 481939 (Poly(dimethylsiloxane), hydroxy terminated, 25 cSt) (all from Sigma, St. Louis, Mo.), FC 770 (3M Electronics, St. Paul, Minn.), XG 2852, SIB 1816 (ABCR Chemicals, Germany), ASC C12, (ABCR Chemicals, Germany), and benzoquinone.
It should be appreciated that the ratio between the size of the hydrophilic head and the lipophilic tail and the nature of the hydrophilic interaction can be adjusted for every type of reagents or applications. In some embodiments, the siloxane based block co-polymers are dimethicones. In some embodiments, the siloxane based block co-polymers are polisolixane-c0-polyglycols co-polymers. In some embodiments, the siloxane based block co-polymers are bis-silanols having a structure of:
wherein n≥10.
In some embodiments, the siloxane based block co-polymers are capable of forming micelles/aggregates. In some embodiments, the siloxane based block co-polymers are immiscible with aqueous liquids such as water and other aqueous buffers. In some embodiments, the siloxane based block co-polymers are miscible with oil. In some embodiments, the siloxane based block co-polymers are stable under certain conditions, e.g., thermal, UV, basic, acidic, etc.
Embodiments disclosed herein include fluidic devices comprising a plurality of droplets dispersed in a filler fluid comprising a siloxane block co-polymer. In some embodiments, the microfluidic device of the present application is an electrowetting device. Electrowetting devices and methods of droplet-based actuation by electrowetting are described in U.S. Patent Publication No. 2004/0055891 the content of which is hereby expressly incorporated by reference in its entirety. The microfluidic device may comprise a droplet actuator. The droplet actuator will include a substrate with one or more electrodes arranged for conducting one or more droplet operations. In some embodiments, the droplet actuator will include one or more arrays, paths or networks of such electrodes. A variety of electrical properties may be employed to effect droplet operations. Examples include electrowetting and electrophoresis.
In some embodiments, a cartridge is coupled to the droplet actuator. The cartridge may include a top plate, often made of plastic, two hydrophobic coating layers, a dielectric coating layer, and a printed circuit board (PCB) bottom with tracks or paths of electrode in between one hydrophobic layer and the dielectric coating layer. The space or gap between the two hydrophobic layers can be filled with the filler fluids disclosed herein. The droplet movement is triggered by the voltage potential of the cartridge.
Embodiments disclosed herein further provide methods of conducting droplet operation in a microfluidic device. Droplet operations may be conducted using a variety of mechanisms, including but not limited to, electrowetting, opto-electrowetting, electrostatic, electrophoretic, dielectrophoretic, electro-osmotic, or a combination thereof.
As used herein, the term “droplet operation” means any manipulation of a droplet on a droplet actuator. A droplet operation may, for example, include: loading a droplet into the droplet actuator; dispensing one or more droplets from a source droplet; splitting, separating or dividing a droplet into two or more droplets; transporting a droplet from one location to another in any direction; merging or combining two or more droplets into a single droplet; diluting a droplet; mixing a droplet; agitating a droplet; deforming a droplet; retaining a droplet in position; incubating a droplet; heating a droplet; vaporizing a droplet; cooling a droplet; disposing of a droplet; transporting a droplet out of a droplet actuator; other droplet operations described herein; and/or any combination of the foregoing. The terms “merge,” “merging,” “combine,” “combining” and the like are used to describe the creation of one droplet from two or more droplets. It should be understood that when such a term is used in reference to two or more droplets, any combination of droplet operations that are sufficient to result in the combination of the two or more droplets into one droplet may be used. For example, “merging droplet A with droplet B,” can be achieved by transporting droplet A into contact with a stationary droplet B, transporting droplet B into contact with a stationary droplet A, or transporting droplets A and B into contact with each other. The terms “splitting,” “separating” and “dividing” are not intended to imply any particular outcome with respect to volume of the resulting droplets (i.e., the volume of the resulting droplets can be the same or different) or number of resulting droplets (the number of resulting droplets may be 2, 3, 4, 5 or more). The term “mixing” refers to droplet operations which result in more homogenous distribution of one or more components within a droplet. Examples of “loading” droplet operations include microdialysis loading, pressure assisted loading, robotic loading, passive loading, and pipette loading.
Droplet operations may be electrode-mediated. In some cases, droplet operations are further facilitated by the use of hydrophilic and/or hydrophobic regions on surfaces and/or by physical obstacles. For examples of droplet operations, see the patents and patent applications cited above under the definition of “droplet actuator.” Impedance or capacitance sensing or imaging techniques may sometimes be used to determine or confirm the outcome of a droplet operation. Examples of such techniques are described in Sturmer et al., U.S. Patent Pub. No. 20100194408, entitled “Capacitance Detection in a Droplet Actuator,” published on Aug. 5, 2010, the entire disclosure of which is incorporated herein by reference.
Generally speaking, the sensing or imaging techniques may be used to confirm the presence or absence of a droplet at a specific electrode. For example, the presence of a dispensed droplet at the destination electrode following a droplet dispensing operation confirms that the droplet dispensing operation is effective. Similarly, the presence of a droplet at a detection spot at an appropriate step in an assay protocol may confirm that a previous set of droplet operations has successfully produced a droplet for detection. Droplet transport time can be quite fast.
For example, in various embodiments, transport of a droplet from one electrode to the next may exceed about 1 sec, or about 0.1 sec, or about 0.01 sec, or about 0.001 sec. In one embodiment, the electrode is operated in AC mode but is switched to DC mode for imaging. It is helpful for conducting droplet operations for the footprint area of droplet to be similar to the electrowetting area. Thus, droplets that are 1×-, 2×- or 3× the default droplet volume are usefully operated using 1, 2, and 3 electrodes, respectively. If the droplet footprint is greater than number of electrodes available for conducting a droplet operation at a given time, the difference between the droplet size and the number of electrodes may not be greater than 1. Thus, a 2× droplet may be usefully controlled using one electrode and a 3× droplet may be usefully controlled using two electrodes. When droplets include beads, it is useful for droplet size to be equal to the number of electrodes controlling the droplet, e.g., transporting the droplet.
In various embodiments, the manipulation of droplets by a droplet actuator may be electrode mediated, e.g., electrowetting mediated or dielectrophoresis mediated or Coulombic force mediated. Examples of other techniques for controlling droplet operations that may be used in the droplet actuators of the present disclosure include using devices that induce hydrodynamic fluidic pressure, such as those that operate on the basis of mechanical principles (e.g. external syringe pumps, pneumatic membrane pumps, vibrating membrane pumps, vacuum devices, centrifugal forces, piezoelectric/ultrasonic pumps and acoustic forces); electrical or magnetic principles (e.g. electroosmotic flow, electrokinetic pumps, ferrofluidic plugs, electrohydrodynamic pumps, attraction or repulsion using magnetic forces and magnetohydrodynamic pumps); thermodynamic principles (e.g. gas bubble generation/phase-change-induced volume expansion); other kinds of surface-wetting principles (e.g. electrowetting, and optoelectrowetting, as well as chemically, thermally, structurally and radioactively induced surface-tension gradients); gravity; surface tension (e.g., capillary action); electrostatic forces (e.g., electroosmotic flow); centrifugal flow (substrate disposed on a compact disc and rotated); magnetic forces (e.g., oscillating ions causes flow); magnetohydrodynamic forces; and vacuum or pressure differential.
In certain embodiments, combinations of two or more of the foregoing techniques may be employed to conduct a droplet operation in a droplet actuator of the present disclosure. Similarly, one or more of the foregoing may be used to deliver liquid into a droplet operations gap, e.g., from a reservoir in another device or from an external reservoir of the droplet actuator (e.g., a reservoir associated with a droplet actuator substrate and a flow path from the reservoir into the droplet operations gap).
Droplet operations surfaces of certain droplet actuators of the present disclosure may be made from hydrophobic materials or may be coated or treated to make them hydrophobic. For example, in some cases some portion or all of the droplet operations surfaces may be derivatized with low surface-energy materials or chemistries, e.g., by deposition or using in situ synthesis using compounds such as poly- or per-fluorinated compounds in solution or polymerizable monomers. Examples include TEFLON® AF (available from DuPont, Wilmington, Del.), members of the CYTOP family of materials, coatings in the FLUOROPEL® family of hydrophobic and superhydrophobic coatings (available from Cytonix Corporation, Beltsville, Md.), silane coatings, fluorosilane coatings, hydrophobic phosphonate derivatives (e.g., those sold by Aculon, Inc), and NOVEC™ electronic coatings (available from 3M Company, St. Paul, Minn.), other fluorinated monomers for plasma-enhanced chemical vapor deposition (PECVD), and organosiloxane (e.g., SiOC) for PECVD.
Droplet transport voltage and frequency may be selected for performance with reagents used in specific assay protocols. Design parameters may be varied, e.g., number and placement of on-actuator reservoirs, number of independent electrode connections, size (volume) of different reservoirs, placement of magnets/bead washing zones, electrode size, inter-electrode pitch, and gap height (between top and bottom substrates) may be varied for use with specific reagents, protocols, droplet volumes, etc. In some cases, a substrate of the present disclosure may be derivatized with low surface-energy materials or chemistries, e.g., using deposition or in situ synthesis using poly- or per-fluorinated compounds in solution or polymerizable monomers. Examples include TEFLON® AF coatings and FLUOROPEL® coatings for dip or spray coating, other fluorinated monomers for plasma-enhanced chemical vapor deposition (PECVD), and organosiloxane (e.g., SiOC) for PECVD.
Additionally, in some cases, some portion or all of the droplet operations surface may be coated with a substance for reducing background noise, such as background fluorescence from a PCB substrate. For example, the noise-reducing coating may include a black matrix resin, such as the black matrix resins available from Toray industries, Inc., Japan. Electrodes of a droplet actuator may be controlled by a controller or a processor, which is itself provided as part of a system, which may include processing functions as well as data and software storage and input and output capabilities. Reagents may be provided on the droplet actuator in the droplet operations gap or in a reservoir fluidly coupled to the droplet operations gap. The reagents may be in liquid form, e.g., droplets, or they may be provided in a reconstitutable form in the droplet operations gap or in a reservoir fluidly coupled to the droplet operations gap. Reconstitutable reagents may be combined with liquids for reconstitution. An example of reconstitutable reagents suitable for use with the methods and apparatus set forth herein includes those described in Meathrel et al., U.S. Pat. No. 7,727,466, entitled “Disintegratable Films for Diagnostic Devices,” issued on Jun. 1, 2010, the entire disclosure of which is incorporated herein by reference.
As used herein, the term “droplet” can mean a volume of liquid on a droplet actuator. In some embodiments, a droplet is at least partially bounded by the filler fluid. For example, a droplet may be completely surrounded by a filler fluid or may be bounded by filler fluid and one or more surfaces of the droplet actuator. As another example, a droplet may be bounded by filler fluid, one or more surfaces of the droplet actuator, and/or the atmosphere. As yet another example, a droplet may be bounded by filler fluid and the atmosphere. Droplets may, for example, be aqueous or non-aqueous or may be mixtures or emulsions including aqueous and non-aqueous components. Droplets may contain solid particles such as magnetic beads.
Droplets may take a wide variety of shapes. Non-limiting examples include generally disc shaped, slug shaped, truncated sphere, ellipsoid, spherical, partially compressed sphere, hemispherical, ovoid, cylindrical, combinations of such shapes, and various shapes formed during droplet operations, such as merging or splitting or formed as a result of contact of such shapes with one or more surfaces of a droplet actuator. For examples of droplet fluids that may be subjected to droplet operations using the approach of the present disclosure, see Eckhardt et al., International Patent Pub. No. WO/2007/120241, entitled, “Droplet-Based Biochemistry,” published on Oct. 25, 2007, the entire disclosure of which is incorporated herein by reference.
In various embodiments, a droplet may include a biological sample, such as whole blood, lymphatic fluid, serum, plasma, sweat, tear, saliva, sputum, cerebrospinal fluid, amniotic fluid, seminal fluid, vaginal excretion, serous fluid, synovial fluid, pericardial fluid, peritoneal fluid, pleural fluid, transudates, exudates, cystic fluid, bile, urine, gastric fluid, intestinal fluid, fecal samples, liquids containing single or multiple cells, liquids containing organelles, fluidized tissues, fluidized organisms, liquids containing multi-celled organisms, biological swabs and biological washes. Moreover, a droplet may include a reagent, such as water, deionized water, saline solutions, acidic solutions, basic solutions, detergent solutions and/or buffers.
A droplet can include nucleic acids, such as DNA, genomic DNA, RNA, mRNA or analogs thereof; nucleotides such as deoxyribonucleotides, ribonucleotides or analogs thereof such as analogs having terminator moieties such as those described in Bentley et al., Nature 456:53-59 (2008); Gormley et al., International Patent Pub. No. WO/2013/131962, entitled, “Improved Methods of Nucleic Acid Sequencing,” published on Sep. 12, 2013; Barnes et al., U.S. Pat. No. 7,057,026, entitled “Labelled Nucleotides,” issued on Jun. 6, 2006; Kozlov et al., International Patent Pub. No. WO/2008/042067, entitled, “Compositions and Methods for Nucleotide Sequencing,” published on Apr. 10, 2008; Rigatti et al., International Patent Pub. No. WO/2013/117595, entitled, “Targeted Enrichment and Amplification of Nucleic Acids on a Support,” published on Aug. 15, 2013; Hardin et al., U.S. Pat. No. 7,329,492, entitled “Methods for Real-Time Single Molecule Sequence Fetermination,” issued on Feb. 12, 2008; Hardin et al., U.S. Pat. No. 7,211,414, entitled “Enzymatic Nucleic Acid Synthesis: Compositions and Methods for Altering Monomer Incorporation Fidelity,” issued on May 1, 2007; Turner et al., U.S. Pat. No. 7,315,019, entitled “Arrays of Optical Confinements and Uses Thereof,” issued on Jan. 1, 2008; Xu et al., U.S. Pat. No. 7,405,281, entitled “Fluorescent Nucleotide Analogs and Uses Therefor,” issued on Jul. 29, 2008; and Ranket al., U.S. Patent Pub. No. 20080108082, entitled “Polymerase Enzymes and Reagents for Enhanced Nucleic Acid Sequencing,” published on May 8, 2008, the entire disclosures of which are incorporated herein by reference; enzymes such as polymerases, ligases, recombinases, or transposases; binding partners such as antibodies, epitopes, streptavidin, avidin, biotin, lectins or carbohydrates; or other biochemically active molecules. Other examples of droplet contents include preparing reagents, such as a reagent for a biochemical protocol, such as a nucleic acid amplification protocol, an affinity-based assay protocol, an enzymatic assay protocol, a polynucleotide sequencing reaction, and/or a protocol for analyses of biological fluids. In one embodiment, a polynucleotide sequencing reaction is a process carried out on a nucleotide sequencing machine, such as a next-generation sequencer, for determining the sequence of nucleotides in a polynucleotide fragment. As used herein, a droplet may include one or more beads.
In some embodiments, the sample or reagent droplet is an aqueous-based. In some other embodiments, the sample or reagent droplet comprises a mixture of water and one or more organic solvents such as alcoholic solvents. In some other embodiments, the sample or reagent droplet contains only one or more organic solvents. In some embodiment, the droplet comprises a biological sample, such as nucleic acid.
The methods of conducting droplet operation in a microfluidic device provided herein may be used for a variety of biomedical applications, such as nucleic acid amplification protocols, affinity-based assay protocols, sequencing protocols, and protocols for analyses of biological fluids, etc.
Some embodiments disclosed herein provide kits comprising a container comprising a filler fluid comprising a siloxane block co-polymer and a filler fluid, and one or more fluidics devices. In one embodiment the fluidics device is an electrowetting device. The filler fluid may include a siloxane block co-polymer and silicone oil. The silicone oil may be PDMS. The kit may also include a container comprising an aqueous buffer, and the aqueous buffer may be substantially immiscible with the siloxane block co-polymer. In some embodiments, less than about 0.1% of the volume fraction of the silicon block co-polymer in the filler fluid is miscible with the aqueous buffer. In some embodiments, the siloxane block co-polymer comprises a siloxane backbone and a functionalized side chain. In some embodiments, the functionalized side chain comprises a hydrophilic head group. In some embodiments, the hydrophilic head group of the siloxane block co-polymer is selected from the group consisting of a polyacrylamide, a polysaccharide, a polyglycol, a carboxylate, a carboxylic acid, a sulfonate, a sulfate, an ethylene glycol, an amine, an ammonium, a carbohydrate, a carbonate, and a silicate. In some embodiments, the siloxane block co-polymer is represented in Formula I:
wherein n≥0, m≥0, and R is selected from the group consisting of a polyacrylamide, a polysaccharide, a polyglycol, a carboxylate, a carboxylic acid, a sulfonate, a sulfate, an ethylene glycol, an amine, an ammonium, a carbohydrate, a carbonate, and a silicate. In some embodiments, the siloxane block co-polymer is selected from the group consisting of CMS-222, CMS-221, FMS 736, FMS-141, APT-263 and MCR-C12. In some embodiments, the concentration of the siloxane block co-polymer in the filler fluid is about 0.02% w/w to about 0.1% w/w. In some embodiments, the concentration of the siloxane block co-polymer in the filler fluid is about 0.05% w/w. In some embodiments, the filler fluid comprises polydimethylsiloxane (PDMS).
Some embodiments disclosed herein provide methods of loading a filler fluid into a microfluidic device comprising a plurality of droplets dispersed in a filler fluid comprising a siloxane block co-polymer solubilized in the filler fluid. In some embodiments, the surface tension between the droplets and the filler fluid is between 3 and 10-12 dynes/cm. In some embodiments, the methods comprise moving the droplets using a mechanism selected from electrowetting, opto-electrowetting, electrostatic, electrophoretic, dielectrophoretic, electro-osmotic, or a combination thereof. In some embodiments, the methods comprise moving the droplets using an electrowetting mechanism.
Additional embodiments are disclosed in further detail in the following examples, which are not in any way intended to limit the scope of the claims.
Multiple siloxane block co-polymer dimethicones were obtained, including several from Momentive (Waterford, N.Y.), such as Silsoft 900 and SF 1528. Another siloxane block co-polymer, known as CMS-222, was obtained from Gelest (Morrisville, Pa.). CMS-222 is a (hydroxypropyleneoxypropyl) methylsiloxane-dimethylsiloxane co-polymer. First, the solubility of these siloxane block co-polymers, and others, were tested in polydimethylsiloxane (PDMS) silicon oil at 1%. Siloxane block co-polymers that were insoluble in PDMS oil were removed from the list. Second, the insolubility in water of these siloxane block co-polymers at 1% was also verified. Soluble siloxane block co-polymers were also removed from the list. Finally the surface tension of water, using the pendant drop method, was tested for the proper concentration of surfactant to achieve the right target level of surface tension. Dimethicones that failed to bring surface tension of oil/water down to about 10 dynes/cm or less were removed from the list. As used herein, a first liquid is soluble in another liquid when the first liquid completely dissolves in the other liquid.
Finally the PDMS oil, spiked with one of these dimethicones, was introduced in a Neoprep™ microassay cartridge, commercially available from Illumina, San Diego, USA. The Neoprep™ cartridge is an electrowetting assay cartridge composed of a bottom plate made from a PCB coated with a dielectric and a hydrophobic layer and a top plate composed of a polymer (polycarbonate) coated with a hydrophobic layer. It was verified that droplets of water could be formed and moved across the surfaces within this filler fluid combination. It was found that filler oil spiked with dimethicone, particularly CMS-222 from Gelest, was found to operate within the cartridge well. Additional testing with Silsoft 900 surfactant also demonstrated that adding a dimethicone surfactant to the oil allowed the device to work very well.
Formulation procedure: An empty 5 L bottle was placed on a scale and Tare weight. 4 L of 5 cSt PDMS oil was added into the 5 L bottle, and bare oil weight was recorded. The Tare weight of bare oil was recorded before adding the silicon block co-polymer CMS-222. 2.0 grams of CMS-222 was added to the 4 L of oil, and actual CMS-222 weight was recorded. If the percentage was not within an acceptable range, extra 5 cSt PDMS oil was added to meet the concentration specifications and the calculation was repeated.
A 3″ magnetic stir bar was placed inside the bottle, and the bottle was capped and moved to a stir plate. The stir speed was set to ˜1½ (vortex occupies about half the solution) and mixed for 1 hour at room temperature. The solution was then transferred into small glass vials, at 8.2 mL dispense volume per vial, and degassed for 3 hours under vacuum (<1 Torr). The target concentration of 0.05% CMS-222 within PDMS was achieved.
Interfacial tension (IFT) for filler fluids having concentrations of 0.02% to 0.1% CMS-222 in 5 cSt PDMS oil were tested against different reagents and water.
IFT working ranges of CMS-222 and Span® 85 (Sigma, St. Louis, Mo.) were tested in reagent A (BBS), reagent B (ESL), and other buffers ERP4, ATL3, QDR, LIG4, SPB, BWS2, FAM, EPM2, PPC2, QSD6 and water. Standard IFT measurements using a pendant drop analysis in oil with CMS 222 and Span® 85 were used. A drop of reagent was pushed out of a syringe needle, into a container with the PDMS oil, until it almost detached from the needle tip. At this point an image was snapped of the hanging drop and its contour profile was analyzed for its shape via the Laplace equation, giving the IFT. The IFT working range was determined by prior functional correlation: <12 dynes/cm for reagent B and >6 dynes/cm for reagent A.
A number of siloxane block co-polymers were tested for their capacity to form micelles or aggregates. They were also tested to determine their range of working concentration, miscibility with water. Even if the co-polymers were only slightly miscible in water they were ruled out. The co-polymers were also tested for their miscibility with the PDMS oil (on a scale of good, pass, bad, fail). Additional factors tested for each of the different co-polymers included their ease of use, handling or preparation (manufacturing friendly). Other factors included their availability, cost, toxicity, flammability and stability (thermal, UV, base, acid, or reagents). We found that siloxane-based surfactants, particularly dimethicones, met all those criteria for use as a block co-polymer within a filler fluid for fluidics devices.
Then, the siloxane block co-polymers were tested for surface tension by measuring IFT at 0.01% against ESL and BBS buffers. The co-polymers that recorded an IFT of about 8-15 mN/m were selected as candidates for use as surfactants. The test results are summarized in
In at least some of the previously described embodiments, one or more elements used in an embodiment can interchangeably be used in another embodiment unless such a replacement is not technically feasible. It will be appreciated by those skilled in the art that various other omissions, additions and modifications may be made to the methods and structures described above without departing from the scope of the claimed subject matter. All such modifications and changes are intended to fall within the scope of the subject matter, as defined by the appended claims.
With respect to the use of plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context or application. The various singular or plural permutations may be expressly set forth herein for the sake of clarity.
It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and/or “an” should be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, means at least two recitations, or two or more recitations).
Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”
In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.
As will be understood by one of skill in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as “up to,” “at least,” “greater than,” “less than,” and the like include the number recited and refer to ranges which can be subsequently broken down into sub-ranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 articles refers to groups having 1, 2, or 3 articles. Similarly, a group having 1-5 articles refers to groups having 1, 2, 3, 4, or 5 articles, and so forth.
This application is a divisional of U.S. patent application Ser. No. 15/770,017, filed on Apr. 20, 2018, which is a 35 U.S.C. § 371 National Stage application of International Patent Application No. PCT/US2016/057941, filed on Oct. 20, 2016, which further claims the priority benefit of U.S. Provisional Patent Application No. 62/245,147, filed Oct. 22, 2015. The entire contents of each of the aforementioned applications are incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| 62245147 | Oct 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15770017 | Apr 2018 | US |
| Child | 16790147 | US |
